Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11902134 | 0.85 | MEN1 (0.36) | LMNACYP3A4GAACYP2C9CYP2C19 | |
| SCHEMBL11902192 | 0.85 | MEN1 (0.36) | LMNACYP3A4GAACYP2C9CYP2C19 | |
| SCHEMBL11902494 | 0.85 | PLG (0.33) | — | |
| SCHEMBL11902598 | 0.85 | PLG (0.33) | — | |
| SCHEMBL11902328 | 0.81 | ABCG2 (0.35) | LMNACYP3A4GAACYP2C9CYP2C19 | |
| SCHEMBL11902296 | 0.79 | GHSR (0.34) | LMNACYP3A4GAACYP2C9CYP2C19 | |
| SCHEMBL11902882 | 0.79 | GHSR (0.34) | LMNACYP3A4GAACYP2C9CYP2C19 | |
| SCHEMBL11902055 | 0.78 | LMNA (0.35) | LMNACYP3A4GAACYP2C9CYP2C19 | |
| SCHEMBL11902791 | 0.78 | LMNA (0.35) | LMNACYP3A4GAACYP2C9CYP2C19 | |
| SCHEMBL12467683 | 0.78 | LMNA (0.32) | LMNACYP3A4GAACYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202794-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202794-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202794-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202794-A1 | COMPOUNDS | HAVCR2, MAVS, GOT2 | LMNA 4549/4885CYP3A4 408/4885GAA 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.